The impact and cost-effectiveness of community-based HIV self-testing in sub-Saharan Africa: a health economic and modelling analysis.


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
03 2019
Historique:
received: 04 05 2018
accepted: 18 01 2019
entrez: 26 3 2019
pubmed: 26 3 2019
medline: 16 7 2020
Statut: ppublish

Résumé

The prevalence of undiagnosed HIV is declining in Africa, and various HIV testing approaches are finding lower positivity rates. In this context, the epidemiological impact and cost-effectiveness of community-based HIV self-testing (CB-HIVST) is unclear. We aimed to assess this in different sub-populations and across scenarios characterized by different adult HIV prevalence and antiretroviral treatment programmes in sub-Saharan Africa. The synthesis model was used to address this aim. Three sub-populations were considered for CB-HIVST: (i) women having transactional sex (WTS); (ii) young people (15 to 24 years); and (iii) adult men (25 to 49 years). We assumed uptake of CB-HIVST similar to that reported in epidemiological studies (base case), or assumed people use CB-HIVST only if exposed to risk (condomless sex) since last HIV test. We also considered a five-year time-limited CB-HIVST programme. Cost-effectiveness was defined by an incremental cost-effectiveness ratio (ICER; cost-per-disability-adjusted life-year (DALY) averted) below US$500 over a time horizon of 50 years. The efficiency of targeted CB-HIVST was evaluated using the number of additional tests per infection or death averted. In the base case, targeting adult men with CB-HIVST offered the greatest impact, averting 1500 HIV infections and 520 deaths per year in the context of a simulated country with nine million adults, and impact could be enhanced by linkage to voluntary medical male circumcision (VMMC). However, the approach was only cost-effective if the programme was limited to five years or the undiagnosed prevalence was above 3%. CB-HIVST to WTS was the most cost-effective. The main drivers of cost-effectiveness were the cost of CB-HIVST and the prevalence of undiagnosed HIV. All other CB-HIVST scenarios had an ICER above US$500 per DALY averted. CB-HIVST showed an important epidemiological impact. To maximize population health within a fixed budget, CB-HIVST needs to be targeted on the basis of the prevalence of undiagnosed HIV, sub-population and the overall costs of delivering this testing modality. Linkage to VMMC enhances its cost-effectiveness.

Identifiants

pubmed: 30907498
doi: 10.1002/jia2.25243
pmc: PMC6432108
doi:

Substances chimiques

Anti-Retroviral Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25243

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Wellcome Trust
ID : 200901/Z/16/Z
Pays : United Kingdom
Organisme : Unitaid
Pays : International

Informations de copyright

© 2019 World Health Organization; licensed by IAS.

Références

Lancet. 2012 Dec 15;380(9859):2129-43
pubmed: 23245605
Lancet HIV. 2016 Sep;3(9):e441-e448
pubmed: 27562745
AIDS Behav. 2010 Jun;14(3):708-15
pubmed: 19623481
Lancet HIV. 2017 Feb;4(2):e83-e92
pubmed: 27863998
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25243
pubmed: 30907498
Lancet HIV. 2016 Jun;3(6):e266-74
pubmed: 27240789
PLoS Med. 2017 Nov 28;14(11):e1002458
pubmed: 29182634
Cochrane Database Syst Rev. 2012 Sep 12;(9):CD001224
pubmed: 22972050
Sex Transm Infect. 2006 Jun;82 Suppl 3:iii18-25
pubmed: 16735288
Lancet. 2014 Jul 19;384(9939):249-56
pubmed: 25042235
PLoS Med. 2017 Nov 21;14(11):e1002442
pubmed: 29161260
Lancet HIV. 2018 Jun;5(6):e277-e290
pubmed: 29703707
Lancet HIV. 2018 Mar;5(3):e146-e154
pubmed: 29174084
J Infect Dis. 2015 Aug 15;212(4):570-7
pubmed: 25767214
Lancet HIV. 2016 May;3(5):e221-30
pubmed: 27126489
Bull World Health Organ. 2014 Jul 1;92(7):499-511AD
pubmed: 25110375
AIDS Behav. 2013 Jun;17(5):1571-90
pubmed: 22752501
Lancet HIV. 2017 Oct;4(10):e457-e464
pubmed: 28801191
AIDS. 2016 Nov 28;30(18):2855-2864
pubmed: 27603290
AIDS. 2018 Mar 13;32(5):645-652
pubmed: 29494424
AIDS. 2016 Nov 13;30(17):2685-2695
pubmed: 27782965
Nature. 2015 Dec 3;528(7580):S77-85
pubmed: 26633769
J Int AIDS Soc. 2016 Feb 15;19(1):20673
pubmed: 26894388
Lancet Infect Dis. 2012 May;12(5):373-80
pubmed: 22277215
Value Health. 2016 Dec;19(8):921-928
pubmed: 27987641
AIDS Behav. 2015 Nov;19(11):1949-65
pubmed: 26054390
Clin Infect Dis. 2018 Apr 3;66(8):1211-1221
pubmed: 29136117
Value Health. 2016 Dec;19(8):929-935
pubmed: 27987642
PLoS One. 2017 Oct 16;12(10):e0185740
pubmed: 29036171
PLoS Med. 2015 Sep 08;12(9):e1001873
pubmed: 26348035
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25255
pubmed: 30907499
PLoS One. 2014 Nov 12;9(11):e108304
pubmed: 25389777
PLoS Med. 2016 Nov 8;13(11):e1002166
pubmed: 27824882
J Int AIDS Soc. 2017 Aug 29;20(Suppl 6):21755
pubmed: 28872271
Nature. 2015 Dec 3;528(7580):S68-76
pubmed: 26633768
J Int AIDS Soc. 2019 Jul;22(7):e25325
pubmed: 31287620

Auteurs

Valentina Cambiano (V)

Institute for Global Health, University College London, London, United Kingdom.

Cheryl C Johnson (CC)

World Health Organization, Geneva, Switzerland.

Karin Hatzold (K)

Population Services International, Washington, DC, USA.

Fern Terris-Prestholt (F)

Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Hendy Maheswaran (H)

Institute of Psychology, Health and Society, University of Liverpool, Liverpool, United Kingdom.

Harsha Thirumurthy (H)

Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Carmen Figueroa (C)

World Health Organization, Geneva, Switzerland.

Frances M Cowan (FM)

Centre for Sexual Health and HIV AIDS Research (CeSHHAR), Harare, Zimbabwe.
Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

Euphemia L Sibanda (EL)

Centre for Sexual Health and HIV AIDS Research (CeSHHAR), Harare, Zimbabwe.
Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

Getrude Ncube (G)

Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.

Paul Revill (P)

Centre for Health Economics, University of York, York, United Kingdom.

Rachel C Baggaley (RC)

World Health Organization, Geneva, Switzerland.

Elizabeth L Corbett (EL)

Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
Department of Clinical Research, London School of Hygiene& Tropical Medicine, London, United Kingdom.

Andrew Phillips (A)

Institute for Global Health, University College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH